Summary of descriptive characteristics of included studies evaluating facility type and characteristics (n = 20), distance traveled to treatment center (n = 11), treatment facility volume (n = 4), and provider expertise (n = 2)
| Author (year) . | Data source years . | US region . | Patients N . | Outcome/analysis . | Cohorts . | HR (95% CI) . | Social determinant associated with worse survival . |
|---|---|---|---|---|---|---|---|
| Treatment facility type and characteristics | |||||||
| Parikh et al,39 (2015) | NCDB 1998-2011 | National | HL 45 777 | OS/multi | Community Comprehensive Academic | Ref. 0.89 (0.79-1.01) 0.78 (0.69-0.89)∗ | Treatment at community center |
| Patel et al,5 (2022) | Institutional 2007-2020 | TX | NHL. 95 | PFS at 2 years | Public Hospital NCI-CCC | 56% 43% | - |
| OS at 2 years | Public Hospital NCI-CCC | 77% 55% | - | ||||
| Dhakal et al,22 (2019) | NCDB 2006-2012 | National | NHL 132 402 | 1-month mortality/uni | Academic Nonacademic | Data not showed | Treatment at nonacademic center |
| 1-month mortality/multi | Academic Nonacademic | Ref. 0.95 (0.86-1.06) | - | ||||
| OS/uni | Academic Nonacademic | 95 vs 78 months∗ | Treatment at nonacademic center | ||||
| OS/multi | Academic Non-academic | Ref. 1.01 (0.97-1.05) | - | ||||
| Go (2016) | NCDB 1998-2011 | National | NHL 278 985 | OS/multi | Academic Comprehensive Community | Ref. 1.05 (1.04-1.07)†, 1.03 (1.01-1.06)† | Treatment at comprehensive or community center |
| Shah (2019) | NCDB 2004-2013 | National | NHL 18 120 | OS/multi | Academic Community Comprehensive | Ref. 1.12 (1.03-1.22)∗, 1.06 (1.00-1.12)∗ | Treatment at community or comprehensive center |
| Ermann (2020) | NCDB 2004-2015 | National | NHL 27 690 | OS/multi | Nonacademic Academic | Ref. 0.86 (NS) | Treatment at nonacademic center |
| Tao et al,25 (2014) | CCR. 2001-2009 | CA | NHL 16 133 | CSS/multi | Non-NCI NCI-designated | Ref. 0.90 (0.84-0.96) | Treatment at non–NCI-designated center |
| OS/multi | No NCI-designated NCI-designated | Ref. 0.96 (0.90-1.01) | Treatment at non–NCI-designated center | ||||
| Ai et al,26 (2012) | CCR. 2001-2008 | CA | NHL 213 | OS/multi | Dx at no NCI-CCC Dx at NCI-CCC | Ref. 0.96 (0.59-1.54) | - |
| Chohan et al,18 (2022) | NCDB 2005-2014 | National | WM. <65 y.o. 1249 | OS/uni | Community Academic | Ref. 0.81 (0.60-1.11) | - |
| OS/multi | Community Academic | Ref. 0.90 (0.62-1.30) | - | ||||
| WM ≥65 y.o. 2629 | OS/uni | Community Academic | Ref. 0.86 (0.75-0.97) | Treatment at community center | |||
| OS/multi | Community Academic | Ref. 0.93 (0.80-1.08) | - | ||||
| Gunaratne et al,35 (2021) | NCBD 2004-2014 | National | WM 3064 | OS/multi | Academic Non-academic | Ref. 0.90 (0.77-1.05) | - |
| Jayakrishnan (2021) | NCDB. 2004-2016 | National | MM 50 543 | OS/multi | Community Comprehensive Academic | Ref. 1.1 (0.97-1.05) 0.95 (0.91-0.98)∗ | Treatment at community center |
| Ho et al,24 (2017) | CCR 1999-2012 | CA | MM 6359 | 1-month mortality/multi | Private Kaiser NCI-designated Teaching | Ref. 0.91 (0.73-1.14) 0.45 (0.36-0.56)∗ 0.92 (0.72-1.19) | Treatment at private hospital |
| Chamoun (2021) | NCDB 2005-2014 | National | MM 117 926 | OS/multi | Academic Other types | Ref. 1.49 (1.39-1.59)∗ | Treatment at community, comprehensive, or integrated center |
| Ailawadhi (2016)‡ | SEER-18 2003-2011 | National | MM 34 529 | OS/multi | 0 NCI centers 1 NCI centers ≥ 2 NCI centers | Ref. 0.99 (0.95-1.04) 0.88 (0.84-0.93)∗ | No access to NCI centers |
| 0 NCCN centers 1 NCCN centers | Ref. 0.91 (0.86-0.95)∗ | No access to NCCN centers | |||||
| Ghiassi-Nejad et al,23 (2019) | NCDB 2004-2013 | National | PM P-bone 4056 | OS/multi | Community Comprehensive Academic/research Integrated | Ref. 0.95 (0.79-1.15) 0.76 (0.62-0.92)∗ 0.97 (0.77-1.22) | Treatment at community center |
| PM P-EM 1468 | OS/multi | Community Comprehensive Academic/research Integrated | Ref. 1.38 (0.98-1.93) 1.29 (0.90-1.84) 1.48 (0.98-2.24) | - | |||
| Master et al,28 (2016) | NCDB 1998 -2012 | National | AML 67 443 | OS/multi | Same facility Different facility | Ref. 0.87 (0.85-0.89)† | Diagnosed and treated at the same facility |
| Bhatt (2017) | NCDB 2003-2011 | National | AML 60 738 | 1-month/multi | Academic Nonacademic | Ref. 1.52 (1.46-1.59)∗ | Treatment at nonacademic center |
| Freeman et al,32 (2016) | NC CCR 2003-2009 | NC | AML 553 | OS/multi | Tx at NCI-CCC Non-NCI-CCC | Ref. 1.25 (0.95-1.65) | - |
| Master et al,28 (2016) | NCDB 1998 -2012 | National | AML 67 443 | OS/multi | Academic Community Comprehensive | Ref. 1.02 (0.98-1.07) 1.04 (1.02-1.06)† | Treatment at comprehensive center |
| Dhakal et al,17 (2022) | NCDB 2004-2015 | National | APL <65 y.o. 5380 | 1-month mortality | Academic Community Comprehensive | Ref. 0.92 (0.37-2.28) 1.18 (0.89-1.57) | - |
| APL ≥65 y.o. 1520 | 1-month mortality | Academic Community Comprehensive | Ref. 1.16 (0.53-2.50) 1.53 (1.14-2.04)∗ | Treatment at comprehensive center | |||
| APL <65 y.o. 5380 | OS/multi | Academic Community Comprehensive | Ref. 0.77 (0.47-1.28) 1.06 (0.90-1.24) | - | |||
| APL ≥65 y.o. 1520 | OS/multi | Academic Community Comprehensive | Ref. 1.17 (0.80-1.69) 1.19 (1.03-1.39)∗ | Treatment at comprehensive center | |||
| Distance traveled (in miles) to treatment center | |||||||
| Loberiza et al,30 (2009) | UNMC 1982-2006 | NE | HL 2330 | OS/multi | NS | NS | - |
| Dhakal et al,22 (2019) | NCDB 2006-2012 | National | NHL 132 402 | OS/multi | < 5.7 5.7-13.3 13.4-36.9 | Ref. 0.96 (0.93-0.98) 0.92 (0.89-0.94)∗ | Distance traveled 13.4 to 36.9 miles |
| Chohan et al,18 (2022) | NCDB 2004-2017 | National | WM. < 65 y.o. 1249 | OS/multi | < 10 10-25 ≥ 25 | Ref. 0.92 (0.59-1.45) 1.49 (0.92-2.41) | - |
| WM ≥ 65 y.o. 2629 | OS/uni | < 10 10-25 ≥ 25 | Ref. 0.89 (0.76-1.04) 0.82 (0.69-0.98)∗ | Distance traveled less than 10 miles | |||
| OS/multi | < 10 10-25 ≥ 25 | Ref. 0.97 (0.81-1.15) 0.95 (0.76-1.19) | - | ||||
| Gunaratne et al,35 (2021) | NCBD 2004-2014 | National | WM 3064 | OS/multi | >20 9–20 4–9 | Ref. 1.1 (0.83-1.26) 1.10 (0.89-1.36) | - |
| Ghiassi-Nejad et al,23 (2019) | NCDB 2004-2013 | National | PM P-bone 4056 | OS/uni | ≤ 12.5 12.6-50 > 50 | Ref. 0.85 (0.76-0.95)∗ 0.87 (0.73-1.04) | Distance less than 12.5 miles |
| PM P-bone 4056 | OS/multi | ≤ 12.5 12.6-50 > 50 | Ref. 0.91 (0.81-1.03) 0.97 (0.79-1.18) | - | |||
| PM P-EM 1468 | OS/multi | ≤ 12.5 12.6-50 > 50 | Ref. 0.98 (0.79-1.21) 0.93 (0.66-1.32) | - | |||
| Bhatt (2017) | NCDB 2003-2011 | National | AML 60 738 | 1-month mortality/multi | ≥ 34.8 0-4.9 5-11.9 | Ref. 1.26 (1.18-1.34)∗, 1.12 (1.05-1.19)∗ | Distance traveled 0 to 11.9 miles |
| Rodriguez et al,33 (2008) | Institutional 1997-2005 | OH | AML 281 | OS/multi | Per 20 increase | 1.00 (0.98-1.02) | - |
| Master et al,28 (2016) | NCDB 1998 -2012 | National | AML 67 443 | OS/multi | ≥ 30 < 30 | Ref. 0.99 (0.97-1.02) | - |
| Freeman et al,32 (2016) | NC CCR 2003-2009 | NC | AML. 553 | OS/multi | < 20 > 20 | Ref. 1.14 (0.85-1.52) | - |
| Borate et al,38 (2015) | SEER 2007-2011 | National | AML. 5541 | OS/uni | < 20 20-70 70-200 | Ref. 0.98 (0.91-1.04) 0.95 (0.89-1.02) | - |
| Dhakal et al,17 (2022) | NCDB 2004-2015 | National | APL <65 y.o. 5380 | 1-month mortality | < 6 6-13.9 14-39.9 | Ref. 0.71 (0.53-0.96)† 0.87 (0.65-1.16) | Distance traveled to less than 6 miles |
| APL ≥65 y.o. 1520 | 1-month mortality/multi | < 6 6-13.9 14-39.9 | Ref. 1.1 (0.70-1.47) 1.01 (0.70-1.46) | - | |||
| APL <65 y.o. 5380 | OS/HR | < 6 6-13.9 14-39.9 | Ref. 0.95 (0.80-1.12) 0.97 (0.82-1.15) | - | |||
| APL ≥65 y.o. 1520 | OS/multi | < 6 6-13.9 14-39.9 ≥ 40 | Ref. 0.92 (0.76-1.12) 1.05 (0.88-1.27) 0.94 (0.77-1.15) | - | |||
| Treatment facility volume (patients treated per year) | |||||||
| Dhakal et al,22 (2019) | NCDB 2006-2012 | National | NHL 132 402 | 1-month mortality/multi | Quartile1: lowest Quartile 2. Quartile 3. Quartile 4: highestc | Ref. 1.1 (0.91-1.13) 0.92 (0.82-1.03) 0.89 (0.78-1.01) | - |
| OS/multi | Quartile1: lowest Quartile 2. Quartile 3. Quartile 4: highestc | Ref. 0.98 (0.95-1.01)∗, 0.96 (0.92-0.99) 0.89 (0.84-0.94)∗ | Treatment at facility with lowest volume | ||||
| Go (2016) | NCDB 1998-2011 | National | NHL 278 985 | OS/multi | Quartile 4: ≥33 Quartile 3: 21-32 Quartile 2:14-20 Quartile 1: 2-13 | Ref. 1.05 (1.04-1.06)∗, 1.08 (1.07-1.10)∗, 1.14 (1.11-1.17)∗ | Treatment at facility with lowest volume |
| Gunaratne et al,35 (2021) | NCBD 2004-2014 | National | WM 3064 | OS/multi | Quartile 4c: highest Quartile 1: lowest Quartile 2 Quartile 3 | Ref. 1.5 (1.18-1.88)∗, 1.4 (1.17-1.72)∗ 1.13 (0.92-1.38) | Treatment at facility with lowest volume |
| Go (2017) | NCDB 2003-2011 | National | MM 94 722 | OS/multi | Quartile 4: >10.3 Quartile 3: 6.2-10.3 Quartile 2: 3.6-6.1 Quartile 1: <3.6 | Ref.b 1.16 (1.1-1.22)∗, 1.23 (1.16-1.3)∗, 1.26 (1.17-1.3)∗ | Treatment at facility with lowest volume |
| Provider expertise | |||||||
| Loberiza et al,30 (2009) | UNMC Database 1982-2006 | NE | HL 2330 | OS/multi | University-based Community-based | Ref. 1.26 (1.06-1.49)∗ | Rural patients treated by community-based providers |
| Shanafelt et al,29 (2012) | The Mayo Clinic CLL Database 1999-2009 | MN | CLL/SLL. 1309 | OS/multi | CLL hematologist Hematologist | Ref. 1.49 (1.08-2.04)∗ | Treatment by a non-CLL hematologist |
| Hematologist Fellow | Ref. 0.98 (0.64-1.50) | - | |||||
| Author (year) . | Data source years . | US region . | Patients N . | Outcome/analysis . | Cohorts . | HR (95% CI) . | Social determinant associated with worse survival . |
|---|---|---|---|---|---|---|---|
| Treatment facility type and characteristics | |||||||
| Parikh et al,39 (2015) | NCDB 1998-2011 | National | HL 45 777 | OS/multi | Community Comprehensive Academic | Ref. 0.89 (0.79-1.01) 0.78 (0.69-0.89)∗ | Treatment at community center |
| Patel et al,5 (2022) | Institutional 2007-2020 | TX | NHL. 95 | PFS at 2 years | Public Hospital NCI-CCC | 56% 43% | - |
| OS at 2 years | Public Hospital NCI-CCC | 77% 55% | - | ||||
| Dhakal et al,22 (2019) | NCDB 2006-2012 | National | NHL 132 402 | 1-month mortality/uni | Academic Nonacademic | Data not showed | Treatment at nonacademic center |
| 1-month mortality/multi | Academic Nonacademic | Ref. 0.95 (0.86-1.06) | - | ||||
| OS/uni | Academic Nonacademic | 95 vs 78 months∗ | Treatment at nonacademic center | ||||
| OS/multi | Academic Non-academic | Ref. 1.01 (0.97-1.05) | - | ||||
| Go (2016) | NCDB 1998-2011 | National | NHL 278 985 | OS/multi | Academic Comprehensive Community | Ref. 1.05 (1.04-1.07)†, 1.03 (1.01-1.06)† | Treatment at comprehensive or community center |
| Shah (2019) | NCDB 2004-2013 | National | NHL 18 120 | OS/multi | Academic Community Comprehensive | Ref. 1.12 (1.03-1.22)∗, 1.06 (1.00-1.12)∗ | Treatment at community or comprehensive center |
| Ermann (2020) | NCDB 2004-2015 | National | NHL 27 690 | OS/multi | Nonacademic Academic | Ref. 0.86 (NS) | Treatment at nonacademic center |
| Tao et al,25 (2014) | CCR. 2001-2009 | CA | NHL 16 133 | CSS/multi | Non-NCI NCI-designated | Ref. 0.90 (0.84-0.96) | Treatment at non–NCI-designated center |
| OS/multi | No NCI-designated NCI-designated | Ref. 0.96 (0.90-1.01) | Treatment at non–NCI-designated center | ||||
| Ai et al,26 (2012) | CCR. 2001-2008 | CA | NHL 213 | OS/multi | Dx at no NCI-CCC Dx at NCI-CCC | Ref. 0.96 (0.59-1.54) | - |
| Chohan et al,18 (2022) | NCDB 2005-2014 | National | WM. <65 y.o. 1249 | OS/uni | Community Academic | Ref. 0.81 (0.60-1.11) | - |
| OS/multi | Community Academic | Ref. 0.90 (0.62-1.30) | - | ||||
| WM ≥65 y.o. 2629 | OS/uni | Community Academic | Ref. 0.86 (0.75-0.97) | Treatment at community center | |||
| OS/multi | Community Academic | Ref. 0.93 (0.80-1.08) | - | ||||
| Gunaratne et al,35 (2021) | NCBD 2004-2014 | National | WM 3064 | OS/multi | Academic Non-academic | Ref. 0.90 (0.77-1.05) | - |
| Jayakrishnan (2021) | NCDB. 2004-2016 | National | MM 50 543 | OS/multi | Community Comprehensive Academic | Ref. 1.1 (0.97-1.05) 0.95 (0.91-0.98)∗ | Treatment at community center |
| Ho et al,24 (2017) | CCR 1999-2012 | CA | MM 6359 | 1-month mortality/multi | Private Kaiser NCI-designated Teaching | Ref. 0.91 (0.73-1.14) 0.45 (0.36-0.56)∗ 0.92 (0.72-1.19) | Treatment at private hospital |
| Chamoun (2021) | NCDB 2005-2014 | National | MM 117 926 | OS/multi | Academic Other types | Ref. 1.49 (1.39-1.59)∗ | Treatment at community, comprehensive, or integrated center |
| Ailawadhi (2016)‡ | SEER-18 2003-2011 | National | MM 34 529 | OS/multi | 0 NCI centers 1 NCI centers ≥ 2 NCI centers | Ref. 0.99 (0.95-1.04) 0.88 (0.84-0.93)∗ | No access to NCI centers |
| 0 NCCN centers 1 NCCN centers | Ref. 0.91 (0.86-0.95)∗ | No access to NCCN centers | |||||
| Ghiassi-Nejad et al,23 (2019) | NCDB 2004-2013 | National | PM P-bone 4056 | OS/multi | Community Comprehensive Academic/research Integrated | Ref. 0.95 (0.79-1.15) 0.76 (0.62-0.92)∗ 0.97 (0.77-1.22) | Treatment at community center |
| PM P-EM 1468 | OS/multi | Community Comprehensive Academic/research Integrated | Ref. 1.38 (0.98-1.93) 1.29 (0.90-1.84) 1.48 (0.98-2.24) | - | |||
| Master et al,28 (2016) | NCDB 1998 -2012 | National | AML 67 443 | OS/multi | Same facility Different facility | Ref. 0.87 (0.85-0.89)† | Diagnosed and treated at the same facility |
| Bhatt (2017) | NCDB 2003-2011 | National | AML 60 738 | 1-month/multi | Academic Nonacademic | Ref. 1.52 (1.46-1.59)∗ | Treatment at nonacademic center |
| Freeman et al,32 (2016) | NC CCR 2003-2009 | NC | AML 553 | OS/multi | Tx at NCI-CCC Non-NCI-CCC | Ref. 1.25 (0.95-1.65) | - |
| Master et al,28 (2016) | NCDB 1998 -2012 | National | AML 67 443 | OS/multi | Academic Community Comprehensive | Ref. 1.02 (0.98-1.07) 1.04 (1.02-1.06)† | Treatment at comprehensive center |
| Dhakal et al,17 (2022) | NCDB 2004-2015 | National | APL <65 y.o. 5380 | 1-month mortality | Academic Community Comprehensive | Ref. 0.92 (0.37-2.28) 1.18 (0.89-1.57) | - |
| APL ≥65 y.o. 1520 | 1-month mortality | Academic Community Comprehensive | Ref. 1.16 (0.53-2.50) 1.53 (1.14-2.04)∗ | Treatment at comprehensive center | |||
| APL <65 y.o. 5380 | OS/multi | Academic Community Comprehensive | Ref. 0.77 (0.47-1.28) 1.06 (0.90-1.24) | - | |||
| APL ≥65 y.o. 1520 | OS/multi | Academic Community Comprehensive | Ref. 1.17 (0.80-1.69) 1.19 (1.03-1.39)∗ | Treatment at comprehensive center | |||
| Distance traveled (in miles) to treatment center | |||||||
| Loberiza et al,30 (2009) | UNMC 1982-2006 | NE | HL 2330 | OS/multi | NS | NS | - |
| Dhakal et al,22 (2019) | NCDB 2006-2012 | National | NHL 132 402 | OS/multi | < 5.7 5.7-13.3 13.4-36.9 | Ref. 0.96 (0.93-0.98) 0.92 (0.89-0.94)∗ | Distance traveled 13.4 to 36.9 miles |
| Chohan et al,18 (2022) | NCDB 2004-2017 | National | WM. < 65 y.o. 1249 | OS/multi | < 10 10-25 ≥ 25 | Ref. 0.92 (0.59-1.45) 1.49 (0.92-2.41) | - |
| WM ≥ 65 y.o. 2629 | OS/uni | < 10 10-25 ≥ 25 | Ref. 0.89 (0.76-1.04) 0.82 (0.69-0.98)∗ | Distance traveled less than 10 miles | |||
| OS/multi | < 10 10-25 ≥ 25 | Ref. 0.97 (0.81-1.15) 0.95 (0.76-1.19) | - | ||||
| Gunaratne et al,35 (2021) | NCBD 2004-2014 | National | WM 3064 | OS/multi | >20 9–20 4–9 | Ref. 1.1 (0.83-1.26) 1.10 (0.89-1.36) | - |
| Ghiassi-Nejad et al,23 (2019) | NCDB 2004-2013 | National | PM P-bone 4056 | OS/uni | ≤ 12.5 12.6-50 > 50 | Ref. 0.85 (0.76-0.95)∗ 0.87 (0.73-1.04) | Distance less than 12.5 miles |
| PM P-bone 4056 | OS/multi | ≤ 12.5 12.6-50 > 50 | Ref. 0.91 (0.81-1.03) 0.97 (0.79-1.18) | - | |||
| PM P-EM 1468 | OS/multi | ≤ 12.5 12.6-50 > 50 | Ref. 0.98 (0.79-1.21) 0.93 (0.66-1.32) | - | |||
| Bhatt (2017) | NCDB 2003-2011 | National | AML 60 738 | 1-month mortality/multi | ≥ 34.8 0-4.9 5-11.9 | Ref. 1.26 (1.18-1.34)∗, 1.12 (1.05-1.19)∗ | Distance traveled 0 to 11.9 miles |
| Rodriguez et al,33 (2008) | Institutional 1997-2005 | OH | AML 281 | OS/multi | Per 20 increase | 1.00 (0.98-1.02) | - |
| Master et al,28 (2016) | NCDB 1998 -2012 | National | AML 67 443 | OS/multi | ≥ 30 < 30 | Ref. 0.99 (0.97-1.02) | - |
| Freeman et al,32 (2016) | NC CCR 2003-2009 | NC | AML. 553 | OS/multi | < 20 > 20 | Ref. 1.14 (0.85-1.52) | - |
| Borate et al,38 (2015) | SEER 2007-2011 | National | AML. 5541 | OS/uni | < 20 20-70 70-200 | Ref. 0.98 (0.91-1.04) 0.95 (0.89-1.02) | - |
| Dhakal et al,17 (2022) | NCDB 2004-2015 | National | APL <65 y.o. 5380 | 1-month mortality | < 6 6-13.9 14-39.9 | Ref. 0.71 (0.53-0.96)† 0.87 (0.65-1.16) | Distance traveled to less than 6 miles |
| APL ≥65 y.o. 1520 | 1-month mortality/multi | < 6 6-13.9 14-39.9 | Ref. 1.1 (0.70-1.47) 1.01 (0.70-1.46) | - | |||
| APL <65 y.o. 5380 | OS/HR | < 6 6-13.9 14-39.9 | Ref. 0.95 (0.80-1.12) 0.97 (0.82-1.15) | - | |||
| APL ≥65 y.o. 1520 | OS/multi | < 6 6-13.9 14-39.9 ≥ 40 | Ref. 0.92 (0.76-1.12) 1.05 (0.88-1.27) 0.94 (0.77-1.15) | - | |||
| Treatment facility volume (patients treated per year) | |||||||
| Dhakal et al,22 (2019) | NCDB 2006-2012 | National | NHL 132 402 | 1-month mortality/multi | Quartile1: lowest Quartile 2. Quartile 3. Quartile 4: highestc | Ref. 1.1 (0.91-1.13) 0.92 (0.82-1.03) 0.89 (0.78-1.01) | - |
| OS/multi | Quartile1: lowest Quartile 2. Quartile 3. Quartile 4: highestc | Ref. 0.98 (0.95-1.01)∗, 0.96 (0.92-0.99) 0.89 (0.84-0.94)∗ | Treatment at facility with lowest volume | ||||
| Go (2016) | NCDB 1998-2011 | National | NHL 278 985 | OS/multi | Quartile 4: ≥33 Quartile 3: 21-32 Quartile 2:14-20 Quartile 1: 2-13 | Ref. 1.05 (1.04-1.06)∗, 1.08 (1.07-1.10)∗, 1.14 (1.11-1.17)∗ | Treatment at facility with lowest volume |
| Gunaratne et al,35 (2021) | NCBD 2004-2014 | National | WM 3064 | OS/multi | Quartile 4c: highest Quartile 1: lowest Quartile 2 Quartile 3 | Ref. 1.5 (1.18-1.88)∗, 1.4 (1.17-1.72)∗ 1.13 (0.92-1.38) | Treatment at facility with lowest volume |
| Go (2017) | NCDB 2003-2011 | National | MM 94 722 | OS/multi | Quartile 4: >10.3 Quartile 3: 6.2-10.3 Quartile 2: 3.6-6.1 Quartile 1: <3.6 | Ref.b 1.16 (1.1-1.22)∗, 1.23 (1.16-1.3)∗, 1.26 (1.17-1.3)∗ | Treatment at facility with lowest volume |
| Provider expertise | |||||||
| Loberiza et al,30 (2009) | UNMC Database 1982-2006 | NE | HL 2330 | OS/multi | University-based Community-based | Ref. 1.26 (1.06-1.49)∗ | Rural patients treated by community-based providers |
| Shanafelt et al,29 (2012) | The Mayo Clinic CLL Database 1999-2009 | MN | CLL/SLL. 1309 | OS/multi | CLL hematologist Hematologist | Ref. 1.49 (1.08-2.04)∗ | Treatment by a non-CLL hematologist |
| Hematologist Fellow | Ref. 0.98 (0.64-1.50) | - | |||||
AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CA, California; CCR, California Cancer Registry; CI, confidential interval; CLL, chronic lymphocytic leukemia; CSS, cancer-specific survival; Dx, diagnosis; HL, Hodgkin lymphoma; HR, Hazard Ratio; MM, Multiple myeloma; MN, Minnesota; multi, Multivariate analysis; N, Sample size; NC, North Carolina; NCDB, National Cancer Database; NC CCR, North Carolina Central Cancer Registry; NCCN, National Comprehensive Cancer Network; NCI-CCC, National Cancer Institute–designated comprehensive cancer center; NHL, non-Hodgkin Lymphoma; NS, not specified; OH, Ohio; P-bone, plasmacytoma originating in bone; P-EM, pasmacytoma originating in extramedullary; PFS, progression-free survival; PM, plasmacytoma; Ref., reference; SEER, Surveillance, Epidemiology, and End Results Registry; SLL, small lymphocytic lymphoma; TX, Texas; Tx, treatment; uni, univariate analysis; UNMC, University of Nebraska Medical Center Oncology Database; WM, Waldenstrom macroglobulinemia; y.o., years old.
Reported as statistical significance by the author.
Statistical significance but not discussed by the author.
Study reported results according to different periods. The most recent year was considered.